03Apr/19
BCMA targeted therapy! GSK antibody drug conjugates apply for sale at the end of the year
British pharmaceutical company GlaxoSmithKline (GSK) recently announced the clinical study DREAMM -1 (NCT02064387) further positive data of experimental anti-B cell mature antigen (BCMA) antibody drug conjugate (ADC) GSK2857916 in the treatment ofRead More…